Online Media

Archives

Select Year2025-20262024-20252023-20242022-2023

• • 

    20 Feb 2026 “We Stayed When Others Left”: Habil F. Khorakiwala on Wockhardt’s 25-Year Battle Against Superbugs
    

  • 

    19 Feb 2026 Wockhardt Limited Receives ESG Rating of 65 (Aspiring) from NSE Sustainability Ratings
    

  • 

    11 Feb 2026 Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%

  • 

    27 Jan 2026 Wockhardt’s Foviscu^® Succeeds in Phase 3 Trial for Drug-Resistant Urinary Tract Infections
    

  • 

    19 Jan 2026 We can launch a new drug every 2 or 3 years, Wockhardt chairman Khorakiwala
    

  • 

    15 Jan 2026 ₹145 to ₹1,397: What made this pharma stock deliver 861% returns in less than 3 yrs?
    

  • 

    10 Jan 2026 Wockhardt Files Marketing Authorisation Application with EMA for Novel Antibiotic WCK 5222

  • 

    8 Jan 2026 Wockhardt files marketing authorisation application for WCK 5222 with EMA

  • 

    8 Jan 2026 Wockhardt Certificate for Quarter Ended December 31, 2025

  • 
    
    

    8 Jan 2026 Wockhardt Submits Marketing Authorisation Application for WCK 5222

  • 

    7 Jan 2026 Wockhardt files marketing application in Europe for its novel antibiotic WCK 5222

  • 

    7 Jan 2026 Wockhardt files Marketing Authorisation Application for WCK 5222 with European Medicines Agency

  • 
    
    

    6 Jan 2026 The year Indian drug innovation bets started paying off

  • 
    
    

    2 Jan 2026 European Medicines Agency grants Accelerated Assessment to Wockhardt’s WCK 5222

  • 
    
    

    1 Jan 2026 Wockhardt Targets European Regulatory Approval for Zaynich by July 2026

  • 
    
    

    1 Jan 2026 Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

  • 
    
    

    1 Jan 2026 Wockhardt ESG Rating Assigned as Excellent

  • 
    
    

    1 Jan 2026 Will Zaynich Drug’s Fast-Track Review Speed Europe Approval?

  • 
    
    

    3 Dec 2025 US FDA Accepts Wockhardt’s NDA for Novel Antibiotic Zaynich

  • 
    
    

    3 Dec 2025 Wockhardt share price jumps 27% in 2 days after US FDA accepts new drug application for breakthrough antibiotic Zaynich

  • 
    
    

    3 Dec 2025 Wockhardt’s Zaynich Wins US FDA NDA Nod, Marking a Landmark Moment

  • 
    
    

    2 Dec 2025 Wockhardt jumps 21% in two days on US FDA nod for Zaynich NDA

  • 
    
    

    2 Dec 2025 US FDA Accepts Wockhardt’s NDA for Novel Antibiotic Zaynich
    

  • 
    
    

    2 Dec 2025 Wockhardt’s Zaynich NDA gets USFDA acceptance: What India’s first NCE means for the company
    

  • 
    
    

    2 Dec 2025 Wockhardt Share Price Gains for the 2nd Straight Day as USFDA Accepts NDA for Antibiotic Zaynich

  • 
    
    

    2 Dec 2025 Wockhardt Stock Soars 6% as USFDA Accepts NDA for New Antibiotic Zaynich

  • 
    
    

    2 Dec 2025 Indian Pharma Breakthrough: Wockhardt’s Zaynich NDA Accepted by US FDA

  • 
    
    

    2 Dec 2025 Share price of Wockhardt rises 27% in 2 days after FDA approves new drug application for breakthrough antibiotic Zaynich

  • 
    
    

    2 Dec 2025 FDA Accepts Wockhardt’s NDA for Breakthrough Antibiotic Zaynich, Marking Historic First for Indian Pharma

  • 
    
    

    2 Dec 2025 FDA accepts Wockhardt’s NDA for breakthrough antibiotic Zaynich

  • 
    
    

    2 Dec 2025 Wockhardt share price jumps 27% in 2 days after US FDA accepts new drug application for breakthrough antibiotic Zaynich

  • 
    
    

    2 Dec 2025 US FDA review boosts odds for Wockhardt’s NCE success story: Vishal Manchanda
    

  • 
    
    

    2 Dec 2025 Wockhardt share price jumps 27% in 2 days after US FDA accepts new drug application for breakthrough antibiotic Zaynich
    

  • 
    
    

    2 Dec 2025 Wockhardt shares extend rally as USFDA accepts NDA for antibiotic Zaynich

  • 
    
    

    2 Dec 2025 Wockhardt Share Price: Pharma stock surges over 6% as USFDA accepts NDA for antibiotic Zaynich
    

  • 
    
    

    2 Dec 2025 Wockhardt shares jump 6%, extend gain to 27% in two days after US FDA accepts new drug application for Zaynich
    

  • 
    
    

    2 Dec 2025 Wockhardt gets NDA status for novel antibiotic Zaynich

  • 
    
    

    1 Dec 2025 Wockhardt jumps over 19% after USFDA accepts its new drug filing

  • 
    
    

    1 Dec 2025 Wockhardt gets NDA status for novel antibiotic Zaynich

  • 
    
    

    1 Dec 2025 Wockhardt soars 19% on huge volumes; here’s why the pharma stock rose today

  • 
    
    

    1 Dec 2025 Wockhardt share price jumps over 19% after US FDA accepts new drug application for Zaynich

  • 
    
    

    1 Dec 2025 US FDA accepts Wockhardt’s new drug application for novel antibiotic Zaynich

  • 
    
    

    1 Dec 2025 Grit, Gamble and a Giant Drug Discovery: Inside Habil Khorakiwala’s Bold Rebuild of Wockhardt and Indian Pharma

  • 
    
    

    1 Dec 2025 “Very confident of positive outcome”: Habil Khorakiwala on USFDA acceptance of Wockhardt’s NDA for its novel antibiotic

  • 
    
    

    1 Dec 2025 Wockhardt shares zoom 20% after USFDA’s historic approval for antibiotic drug Zaynich

  • 
    
    

    1 Dec 2025 Wockhardt Makes History: USFDA Accepts First-Ever NDA from Indian Pharma

  • 
    
    

    1 Dec 2025 US FDA Accepts Wockhardt’s New Drug Application For Breakthrough Antibiotic Zaynich

  • 
    
    

    1 Dec 2025 First‑In‑Class Indian Antibiotic Zaynich Gets US FDA Acceptance

  • 
    
    

    16 Oct 2025 India’s New Antibiotic in 30 Years Offers Hope Against Antibacterial-Resistant Infections

     

  • 
    
    

    10 Oct 2025 India’s New Antibiotic ‘Zaynich’ Targets Deadly Superbugs: A Breakthrough After 30 Years

     

  • 
    
    

    8 Oct 2025 ‘Cough Syrup Tragedy Calls For Regulatory Reform’: Wockhardt Chief Habil Khorakiwala To News18

     

  • 
    
    

    8 Oct 2025 India Develops Homegrown Antibiotic Zaynich to Combat Multi-Drug Resistant Infections

     

  • 
    
    

    7 Oct 2025 Wockhardt Submits New Drug Application to USFDA for Zidebactam-Cefepime

     

  • 
    
    

    6 Oct 2025 India Develops Homegrown Antibiotic Zaynich To Fight Multi-Drug Resistant Infections

     

  • 
    
    

    3 Oct 2025 Wockhardt files FDA NDA for Zidebactam-Cefepime antibiotic
    

     

  • 
    
    

    3 Oct 2025 Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich

     

  • 
    
    

    3 Oct 2025 India develops powerful, homegrown antibiotic after 30 years – shorter dosage, greater efficacy, and more

     

  • 
    
    

    3 Oct 2025 India Unveils Powerful ‘Homegrown Antibiotic’ Against Drug-Resistant Bacteria

     

  • 
    
    

    3 Oct 2025 After 30 years, a powerful new antibiotic is born in India

     

  • 
    
    

    1 Oct 2025 Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

     

  • 
    
    

    1 Oct 2025 Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

     

  • 
    
    

    30 Sept 2025 After 30 years, a powerful new antibiotic is born in India

     

  • 
    
    

    8 Sept 2025 The world needs new antibiotics. Can India deliver them?
    

     

  • 
    
    

    12 Aug 2025 Wockhardt Eyes ‘Healthy Bottom Line’ In Coming Quarters Amid US Tariff Concerns
    

     

  • 
    
    

    30 July 2025 How Wockhardt’s bet on multi-drug resistant infections is paying off
    

     

  • 
    
    

    21 July 2025 From near bankruptcy to blockbuster drug: How Khorakiwala turned around Wockhardt
    

     

  • 
    
    

    14 July 2025 Wockhardt shares rise 2% after exiting US generics business
    

     

  • 
    
    

    14 July 2025 Wockhardt turns focus to biosimilars and innovation, targets stronger margins
    

     

  • 
    
    

    11 July 2025 Wockhardt exits US generics business, files for liquidation of subsidiaries
    

     

  • 
    
    

    11 July 2025 Wockhardt exits its US generics business

     

  • 
    
    

    11 July 2025 Wockhardt to exit US generic pharma segment, shut down 2 subsidiaries
    

     

  • 
    
    

    1 July 2025 Wockhardt activates Zaynich push, eyes global licensing deals
    

     

  • 
    
    

    6 June 2025 Wockhardt has high hopes for novel antibiotic Zaynich

     

  • 
    
    

    6 June 2025 Wockhardt eyes $7 bn mkt opp for antibiotic Zaynich

     

  • 
    
    

    5 June 2025 Wockhardt’s Zaynich: USD 7bn Market Opportunity

     

  • 
    
    

    5 June 2025 Wockhardt eyes mid-2026 India launch for new drug Zaynich: Chairman Khorakiwala

     

  • 
    
    

    5 June 2025 Wockhardt files for regulatory approval of novel antibiotic Zaynich

     

  • 
    
    

    5 June 2025 Wockhardt looking at FY27 US launch for ‘miracle’ antibiotic Zaynich

     

  • 
    
    

    5 June 2025 Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

     

  • 
    
    

    5 June 2025 Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe

     

  • 
    
    

    29 May 2025 Wockhardt Q4 earnings: Net loss narrows to Rs 45 crore; revenue, EBITDA and more

     

  • 
    
    

    29 May 2025 Wockhardt Q4 Results: Loss narrows to ₹45 crore, revenue up 6% YoY

     

  • 
    
    

    23 May 2025 As we continue to tackle the challenges of antimicrobial resistance, time to factor in newer, emergent issues

     

  • 
    
    

    09 Apr 2025 Wockhardt Bio incorporates new wholly owned subsidiary in Ireland

     

  • 
    
    

    03 Apr 2025 How Wockhardt is packing for the road less travelled

     

  • 
    
    

    01 Apr 2025 Wockhardt Zaynich successfully treats Paediatric cancer patient with recalcitrant blood, liver infection

     

  • 
    
    

    01 Apr 2025 Wockhardt surges after breakthrough US cancer treatment with Zaynich

     

  • 
    
    

    04 Mar 2025 Wockhardt On Superbug Buster Zaynich, US Tariff Talk, Europe Manufacture

     

  • 
    
    

    10 Feb 2025 Wockhardt posts Q3 net profit at Rs. 20 Cr

     

  • 
    
    

    3 Feb 2025 Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study

     

  • 
    
    

    17 Jan 2025 Novel Antibiotics: Is Regional Research a solution?

     

  • 
    
    

    17 JAN 2025 Wockhardt’s ‘miracle drug’ Zaynich: Can it revive the antibiotics market and the company’s fortunes?

     

  • 
    
    

    13 JAN 2025 Wockhardt shares jump 4% despite the stock market crash after an update on antibiotic Zaynich

     

  • 
    
    

    13 JAN 2025 Zaynich shows over 97 percent efficacy for drug-resistant bacteria: Wockhardt

     

  • 
    
    

    5 JAN 2025 CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia

     

  • 
    
    

    3 JAN 2025 Wockhardt’s novel antibiotic gets regulatory approval

     

  • 
    
    

    3 JAN 2025 Wockhardt shares hit 52-week high as CDSCO okays pneumonia drug

     

  • 
    
    

    2 JAN 2025 CDSCO approves Wockhardt’s drug Miqnaf to treat CABP in adults

     

  • 
    
    

    17 DEC 2024 Wockhardt’s New drug ‘helps US patient’

     

  • 
    
    

    16 DEC 2024 Why this pharma stock hit nearly 9-year high; froze at 10% upper circuit?

     

  • 
    
    

    12 DEC 2024 Wockhardt’s Wonder Drug – new antibiotic tipped to save millions of lives

     

  • 
    
    

    12 DEC 2024 India’s Superbug Superpower: Upcoming Antibiotics Tipped To Save Millions Of Lives From Point Of No Return

     

  • 
    
    

    6 DEC 2024 Indigenous development of Nafithromycin marks key milestone in AMR battle: Government

     

  • 
    
    

    5 DEC 2024 Revolutionary Breakthrough: India’s First Indigenous Antibiotic Nafithromycin Fights Drug-Resistant Pneumonia

     

  • 
    
    

    5 DEC 2024 INDIA’S ‘BLOCKBUSTER’ DRUGS TO TAKE ON DEADLY SUPERBUGS

     

  • 
    
    

    4 DEC 2024 INDIA DEVELOPS ANTIBIOTIC THAT PROVIDES EIGHT TIMES HIGHER EFFICACY THAN AZITHROMYCIN

     

  • 
    
    

    28 NOV 2024 ALL ABOUT NAFITHROMYCIN, FIRST ANTIBIOTIC DEVELOPED IN INDIA AGAINST DEADLY, DRUG-RESISTANT BACTERIA

     

  • 
    
    

    20 NOV 2024 REVOLUTIONIZING ANTIBIOTIC AFFORDABILITY: A CALL FOR GST EXEMPTION ON INDIAN DISCOVERIES

     

  • 
    
    

    14 NOV 2024 WOCKHARDT STANDALONE SEPTEMBER 2024 NET SALES AT RS 370.00 CRORE, UP 42.31% Y-O-Y

     

  • 
    
    

    13 NOV 2024 WOCKHARDT NARROWING LOSSES: A FINANCIAL TURNAROUND?
    

     

  • 
    
    

    12 NOV 2024 WOCKHARDT RAISES ₹1,000 CRORE BY SELLING SHARES TO INSTITUTIONS — FIND OUT THE LIST OF ALLOTTEES
    

     

  • 
    
    

    11 Nov 2024 Wockhardt QIP bids dominated by major mutual funds

     

  • 
    
    

    2 Nov 2024 Why Are Investors Betting Big On Wockhardt After 10 Years Of Being ‘Wealth Destroyer’? One Factor That Changed Company’s Fortune

     

  • 
    
    

    17 Oct 2024 Wockhardt seeks DCGI Nod to market aspart insulin injection

     

  • 
    
    

    16 Oct 2024 Wockhardt files its Aspart insulin injection with DCGI

     

  • 
    
    

    16 Oct 2024 Wockhardt approaches DCGI for marketing approval for diabetes drug

     

  • 
    
    

    16 Oct 2024 Wockhardt files its Aspart insulin injection with DCGI

     

  • 
    
    

    16 Oct 2024 Wockhardt files new fast-acting insulin with DCGI, shares surge

     

  • 
    
    

    16 Oct 2024 Wockhardt files indigenous fast-acting insulin injection with DCGI, shares rise 4%

     

  • 
    
    

    16 Oct 2024 Wockhardt files fast-acting Insulin Aspart injection with DCGI

     

  • 
    
    

    16 Oct 2024 Wockhardt seeks DCGI approval on its version of Aspart insulin

     

  • 
    
    

    14 Oct 2024 Received CDSCO nod for Nafithromycin Antibiotic for CABP, says Wockhardt

     

  • 
    
    

    14 Oct 2024 Wockhardt’s antibiotic Miqnaf recommended by CDSCO

     

  • 
    
    

    14 Oct 2024 Wockhardt locks in 5% upper circuit as it nears approval for pneumonia drug
    

    14 Oct 2024 Wockhardt locks in 5% upper circuit as it nears approval for pneumonia drug

  • 
    
    

    14 Oct 2024 Indian drug regulator recommends Wockhardt’s Miqnaf for treatment of CABP
    

     

  • 
    
    

    11 Oct 2024 Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP

     

  • 
    
    

    11 Oct 2024 CDSCO committee recommends Wockhardt’s novel antibiotic Miqnaf for CABP treatment

     

  • 
    
    

    11 Oct 2024 Wockhardt Shares Hit Upper Circuit After Pneumonia Drug Boost

     

  • 
    
    

    11 Oct 2024 Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP

     

  • 
    
    

    11 Oct 2024 Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP

     

  • 
    
    

    08 Oct 2024 FDA grants fast track designation to Wockhardt’s novel antibiotic WCK 6777

     

  • 
    
    

    08 Oct 2024 USFDA grants fast track designation to Wockhardt novel antibiotic WCK 6777

     

  • 
    
    

    07 Oct 2024 Wockhardt’s WCK 6777 earns Fast Track Designation from USFDA

     

  • 
    
    

    07 Oct 2024 Wockhardt’s Innovative antibiotic receives FDA fast-Track Designation, stock surges

     

  • 
    
    

    07 Oct 2024 Wockhardt’s WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I Study

     

  • 
    
    

    07 Oct 2024 Wockhardt’s antibiotic gets Fast Track designation from USFDA

     

  • 
    
    

    07 Oct 2024 Wockhardt’s once-a-day antibiotic drug ‘WCK 6777’ successfully concludes Phase I study

     

  • 
    
    

    07 Oct 2024 US FDA grants fast track status to Wockhardt’s novel antibiotic WCK 6777

     

  • 
    
    

    07 Oct 2024 Wockhardt’s new antibiotic WCK 6777 gains FDA fast track status, completes phase I trial, stocks decline

     

  • 
    
    

    07 Oct 2024 WCK 6777 passes trials; FDA grants fast track status to antibiotic for complicated UTIs

     

  • 
    
    

    04 Oct 2024 Dr Habil Khorakiwala honoured with Lifetime Achievement Award at 10th IHW summit

     

  • 
    
    

    01 Oct 2024 Dr Habil Khorakiwala bags Lifetime Achievement Award at 10th Integrated Health C Wellbeing Summit in Dubai

     

  • 
    
    

    27 Sept 2024 Wockhardt group Founder Chairman Dr Habil Khorakiwala bags Lifetime Achievement Award at 10th IHW summit in Dubai

     

  • 
    
    

    27 Sept 2024 Dr. Habil Khorakiwala honoured with Lifetime Achievement Award

     

  • 
    
    

    27 Sept 2024 Dr. Habil Khorakiwala Honored with Lifetime Achievement Award

     

  • 
    
    

    26 Sept 2024 Dr Habil Khorakiwala honored with Lifetime Achievement Award

     

  • 
    
    

    25 Sept 2024 Lifetime Achievement Award Presented to Dr. Habil Khorakiwala Wockhardt Founder

     

  • 
    
    

    23 Sept 2024 Wockhardt’s Antibiotic Zaynich To Be Available In India At 80% Discount To US Price

     

  • 
    
    

    23 Sept 2024 Wockhardt founder Dr. Habil Khorakiwala honored with lifetime achievement award

     

  • 
    
    

    20 Sept 2024 Wockhardt targets global launch of new meningitis drug with $6 bn market potential by 2026

     

  • 
    
    

    20 Sept 2024 Wockhardt’s Zaynich cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use

     

  • 
    
    

    19 Sept 2024 Wockhardt’s investigational drug, Zaynich demonstrates its ability to manage complex infections

     

  • 
    
    

    19 Sept 2024 Wockhardt’s investigational drug, Zaynich™ demonstrates its ability to manage complex infections

     

  • 
    
    

    19 Sept 2024 India’s Wockhardt up after drug found effective in meningitis case

     

  • 
    
    

    18 Sept 2024 Wockhardt Chairman Dr Habil Khorakiwala conferred with BIRAC Innovator Award 2024

     

  • 
    
    

    18 Sept 2024 Wockhardt Chairman Dr Habil Khorakiwala conferred with BIRAC Innovator Award 2024

     

  • 
    
    

    16 Sept 2024 Wockhardt clinches BIRAC innovator award for novel antibiotic

     

  • 
    
    

    16 Sept 2024 BIRAC awards Wockhardt’s Chairman Dr Habil Khorakiwala for Nafithromycin innovation

     

  • 
    
    

    16 Sept 2024 Wockhardt wins “BIRAC Innovator Award 2024”

     

  • 
    
    

    3 Sept 2024 CDSCO Panel approves Wockhardt’s Protocol Amendment proposal for antimicrobial drug cefepime plus zidebactam

     

  • 
    
    

    1 Jul 2024 Wockhardt soars as Zaynich shows promise against superbugs

     

  • 
    
    

    1 Jul 2024 Wockhardt shares skyrocket 18% to fresh 52-week high. Here’s why?

     

  • 
    
    

    1 Jul 2024 Multibagger stock! Wockhardt shares rally 16% to hit new 52-wk high; here’s why

     

  • 
    
    

    1 Jul 2024 Wockhardt stock soars over 19% after its investigational antibiotic Zaynich successfully treats cancer patient in US

     

  • 
    
    

    1 Jul 2024 Wockhardt soars as Zaynich shows promise against superbugs

     

  • 
    
    

    1 Jul 2024 Why Wockhardt Share Price is Rising

     

  • 
    
    

    1 Jul 2024 Wockhardt to Launch Antibiotic Zaynich with USD 25 Billion Market Potential

     

  • 
    
    

    1 Jul 2024 Globally renowned US body CLSI awards high susceptibility breakpoints to Zaynich

     

  • 
    
    

    1 Jul 2024 CLSI awards high susceptibility breakpoints to Zaynich

     

  • 
    
    

    1 Jul 2024 US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222)

     

  • 
    
    

    1 Jul 2024 Wockhardt On Future Growth Prospects, WCK 5222 & FY25 Product Pipeline | Dr. Habil Khorakiwala

     

  • 
    
    

    1 Jul 2024 Wockhardt plans to launch antibiotic Zaynich in early FY26

     

  • 
    
    

    30 Jun 2024 City pharma’s new antibiotic to combat superbugs by year-end

     

  • 
    
    

    29 Jun 2024 Wockhardt Says Antibiotic Zaynich Showing Efficacy in Trials, Aims to Launch It by Early Financial Year 2026-2027

     

  • 
    
    

    29 Jun 2024 Antibiotic Zaynich Showing Efficacy in Trials, Says Wockhardt Pharma

     

  • 
    
    

    29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

     

  • 
    
    

    29 Jun 2024 Wockhardt to Launch Groundbreaking Antibiotic Zaynich in India by 2025

     

  • 
    
    

    29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

     

  • 
    
    

    29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt’s novel antibiotic Zaynich to be launched in India by end of FY25

     

  • 
    
    

    28 Jun 2024 Wockhardt Launches New Antibiotic With $25-Billion Market Potential

     

  • 
    
    

    28 Jun 2024 Wockhardt Launches New Antibiotic With $25-Billion Market Potential Manage your data

     

  • 
    
    

    28 Jun 2024 Here’s why shares of Wochardt Pharma surged by 5% on Friday

     

  • 
    
    

    28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt Aims to Launch Billion-Dollar Antibiotic Zaynich by FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt’s novel antibiotic Zaynich to be launched in India by end of FY25

     

  • 
    
    

    28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

     

  • 
    
    

    28 Jun 2024 Wockhardt likely to get DCGI nod for respiratory drug by year-end; stock up 5%

     

  • 
    
    

    28 Jun 2024 Wockhardt claims breakthrough in drug-resistant infection in cancer patients with experimental drug Zaynich; US body awards highest susceptibility to the antibiotic

     

  • 
    
    

    28 Jun 2024 Wockhardt’s investigational antibiotic shows significant effectiveness in global Phase 3 trials

     

  • 
    
    

    28 Jun 2024 Here’s why shares of Wockhardt Pharma surged by 5% on Friday

     

  • 
    
    

    28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26

     

  • 
    
    

    11 Mar 2024 Wockhardt announces success of antibiotic to treat drug-resistant infection

     

  • 
    
    

    12 Jan 2024 Wockhardt has more antibiotics in the pipeline: Dr Habil Khorakiwala

     

  • 
    
    

    14 Dec 2023 An antibiotics pipeline holds out promise for Wockhardt

     

  • 
    
    

    11 Dec 2023 Wockhardt completes phase 3 study on Nafithromycin for pneumonia, shares surge

     

  • 
    
    

    11 Dec 2023 Wockhardt shares zoom 19% to hit one-year high; here’s why

     

  • 
    
    

    11 Dec 2023 Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now

     

  • 
    
    

    11 Dec 2023 Wockhardt completes Phase 3 pneumonia study of macrolide antibiotic Nafithromycin WCK 4873

     

  • 
    
    

    11 Dec 2023 Wockhardt soars 19% on completion of phase-3 study of pneumonia drug

     

  • 
    
    

    11 Dec 2023 Wockhardt shares hit 52-week high, rally over 18%; here’s why

     

  • 
    
    

    11 Dec 2023 Wockhardt Stocks Hit Rs 398.95, a 52-Week High on Phase 3 Pneumonia Antibiotic Success
    

     

  • 
    
    

    11 Dec 2023 Wockhardt Ltd Share surges 19 percent today sudden expert says stock may go up to Rs 450

     

  • 
    
    

    19 July 2023  Journalistic Influence on Pharma Giants: Journalist Amelia Fernandes Joins Wockhardt’s Board

     

  • 
    
    

    9 July 2023  Wockhardt charting a recovery riding on a promising new antibiotic

     

  • 
    
    

    14 June 2023   Successful Use of WCK 5222 in an Adult Patient with Acute T-Cell Leukemia

     

  • 
    
    

    31 Mar 2023   Wockhardt Aims For $12m Annual Savings Through US Restructuring

    22 February, 2023

  • 
    
    

    22 Feb 2023    Wockhardt to restructure US business to save $12 million per year, sees debt pare down

    22 February, 2023

  • 
    
    

    22 Feb 2023    At a turning point. Wockhardt in talks for vaccine manufacture in the UK

    22 February, 2023

  • 
    
    

    21 Feb 2023    A Game-Changer: India’s Under-Trial Drug Shows Promise Against Hospital Superbugs

    21 February, 2023

  • 
    
    

    12 Feb 2023    Under-trial antibiotic use saves minor thalassemia patient’s life

    12 February, 2023

  • 
    
    

    13 Nov 2022   Desi antibiotic under trial in Europe saves woman’s life
    

    13 November, 2022

  • 
    
    

    13 Nov 2022   Under-trial antibiotic cleared superbug infection in 5 days

    13 November, 2022

  • 
    
    

    5 Sep 2022       Wockhardt receives affirmation in credit ratings from CARE
    

    5 September, 2022

  • 
    
    

    26 Aug 2022    Will restructuring US biz turnaround this pharma player?

    26 August, 2022

  • 
    
    

    20 Aug 2022    Wockhardt ties up with various partners to roll out products in US market

    16 August, 2022

  • 
    
    

    16 Aug 2022    Wockhardt initiates phase-III clinical study of new antibiotic candidate

    16 August, 2022